Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Business Overview: Curis is a therapeutic drug development company focused on modulating regulatory signaling pathways (e.g., Hedgehog, BMP) for tissue growth and repair. The company operates in a single segment and relies heavily on strategic collaborations (Genentech, Wyeth, Procter & Gamble) for funding and development. It has no commercial products to date and has never been profitable.
Key Financial Metrics
| Metric | Q1 2006 | Q1 2005 |
|---|---|---|
| Net Revenues | $2,038,430 | $(812,748) |
| Gross Revenues | $2,864,530 | $2,491,754 |
| Net Loss | $(4,048,994) | $(5,381,314) |
| Loss Per Share (Basic/Diluted) | $(0.08) | $(0.11) |
| Cash and Cash Equivalents | $23,148,555 | $22,310,298 (Dec 31, 2005) |
| Marketable Securities | $19,866,847 | $21,899,024 (Dec 31, 2005) |
| Total Current Assets | $44,919,107 | $45,892,153 (Dec 31, 2005) |
| Total Current Liabilities | $8,960,841 | $9,881,078 (Dec 31, 2005) |
| Long-Term Debt (Net of Current) | $1,658,333 | $1,966,667 (Dec 31, 2005) |
| Accumulated Deficit | $(684,103,167) | $(680,054,173) (Dec 31, 2005) |
Cash Flow Summary (Three Months Ended March 31, 2006):
- Net cash used in operating activities: $(873,278)
- Net cash provided by investing activities: $2,017,788
- Net cash used in financing activities: $(306,253)
Material Changes vs. Prior Period
- Revenue Improvement: Net revenue turned positive ($2.04M) compared to a negative net revenue of $(0.81M) in Q1 2005. This was primarily driven by a $2.48M decrease in "contra-revenues" (cost reimbursements to Genentech) compared to the prior year, alongside a 15% increase in gross revenues.
- Expense Increases:
- Research & Development (R&D): Increased 14% to $3.48M, driven by a $525k increase in discovery research and a significant increase in stock-based compensation due to the adoption of SFAS 123(R).
- General & Administrative (G&A): Increased 70% to $2.89M. The primary driver was a $506k increase in stock-based compensation expense. Legal services also rose 110% due to patent costs and financial statement restatement efforts.
- Debt Reduction: The company converted a $2.64M convertible note payable to Becton Dickinson into common stock in January 2006, eliminating that specific debt obligation.
- Stock-Based Compensation: The adoption of SFAS 123(R) on January 1, 2006, resulted in the recognition of $832,000 in stock-based compensation expense for the quarter, compared to only $2,000 in the prior year period.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Liquidity:
- Management expects to maintain operations into at least the second half of 2007 using existing cash resources and contractually defined payments from collaborators.
- The company anticipates incurring substantial operating losses for the foreseeable future and does not expect to achieve profitability in the near term.
- Additional financing (equity or debt) will likely be required beyond 2007, which may result in dilution.
Recent Developments:
- Genentech Collaboration: In May 2006, Curis entered an amendment to extend research funding with Genentech for up to $918,750. Preliminary Phase I data for the basal cell carcinoma candidate showed less clinical activity than anticipated, leading to a temporary suspension of enrollment in the second segment of the trial.
- Procter & Gamble: Curis received a $1.0M payment for achieving a preclinical milestone in the hair growth program. This is being recognized as revenue over time rather than as a substantive milestone.
Risks and Contingencies:
- Financial Restatement: The company restated financial results for 2003, 2004, and 2005 due to accounting errors regarding revenue recognition (specifically $7.5M in Genentech payments) and R&D expenses. This exposes the company to potential securities litigation.
- Genentech Dispute: Genentech claims Curis owes an additional $667,000 in co-development costs. Curis disputes the full amount but has accrued a liability of $325,000, estimating the final liability could range up to $667,000.
- Sublease Risk: A subtenant at Curis's Cambridge facility may default. Curis has accrued a $550,000 loss related to potential vacancy costs.
- Micromet Litigation: Curis is pursuing a claim in Germany for approximately EUR 2.0M from a former collaborator (Micromet), but collection is not considered probable as of the filing date.
Investor Verification Checklist
- Restatement Impact: Verify the full extent of the financial restatement for 2003-2005 and any ongoing legal or regulatory consequences.
- Genentech Trial Status: Monitor the final results of the Phase I basal cell carcinoma trial and the decision on whether to proceed to Phase II, given the preliminary data showed less activity than expected.
- Genentech Cost Dispute: Track the resolution of the $667,000 invoicing dispute to determine the final liability impact.
- Liquidity Runway: Confirm the company's cash burn rate and the sufficiency of funds to operate through the second half of 2007 without immediate dilutive financing.
- Sublease Default: Monitor the status of the subtenant at 61 Moulton Street to assess if the accrued $550,000 loss will materialize or if a new subtenant can be found.